Longitudinal Blood Eosinophil Profiles and Response to Anti-IL-5/IL-5Rα Biologics in Severe Asthma.
Betancor Diana D, Laorden Daniel D, Rozo Mariana M, Vecillas Leticia De Las LL et al.
Aurobindo Pharma Limited · VEGFA · 单克隆抗体
bevacizumab 是一种单克隆抗体,由Aurobindo Pharma Limited研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。
| 商品名 | BP 01, Bevqolva, BP01 |
| 公司 | Aurobindo Pharma Limited |
| 药物类别 | 单克隆抗体, 抗体 |
| 分子靶点 | VEGFA |
| 给药途径 | Injectable (Others), Intravenous (IV) |
| 状态 | Approved |
bevacizumab 作用于 1 个分子靶点:
| VEGFA | vascular endothelial growth factor A (VPF, MVCD1) |
bevacizumab 针对 9 个适应症,涉及 2 个治疗领域。
| 治疗领域 | 疾病/病症 | 分期 |
|---|---|---|
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Non-small cell lung cancer stage IV | ✓ Approved |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Non-small cell lung cancer metastatic | ✓ Approved |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Ovarian cancer | ✓ Approved |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Renal cancer | ✓ Approved |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Colorectal cancer | ✓ Approved |
注册免费账户还可查看另外 4 个适应症
免费注册查看全部适应症 →Betancor Diana D, Laorden Daniel D, Rozo Mariana M, Vecillas Leticia De Las LL et al.
Kayikci Mahmutoglu Gulce G, Simsek Metehan M, Cevik Sadik Gorkem SG, Arici Murat M et al.
Post-injection endophthalmitis (PIE) is a rare, vision-threatening complication of intravitreal injections (IVIs). As IVI volumes rise globally, optimising prevention and management is crucial. This study evaluated PIE incidence, risk factors, microbiology, and outcomes over ten years. A retrospective cohort study of 224,397 IVIs. We analysed demographics, agent type, and preparation (pre-filled syringe [PFS] vs. manual aliquoting). Overall endophthalmitis incidence was 0.029% (n = 65), and 0.026% for anti-VEGFs. PFS-ranibizumab had the lowest incidence (0.014%) and was significantly safer than manually prepared bevacizumab (0.039%; OR: 2.74 [95% CI: 1.36-5.55], p = 0.003); vial-sourced aflibercept (0.027%) was intermediate and not statistically distinguishable from either. Culture positivity was 33.8% (n = 22), predominantly Gram-positive (81.8%), with Staphylococcus epidermidis being the most common (45.5%). In univariate analysis, culture positivity was the sole predictor of worse final visual acuity (VA) (p = 0.030), though limited by small sample sizes. Median VA worsened from 0.61 logMAR at baseline to 2.10 logMAR at presentation, recovering to 1.80 logMAR at final visit (p < 0.001). Among cases initially treated with tap and intravitreal antibiotics (TAI), 60% (21/35) required subsequent vitrectomy (PPV). No baseline clinical parameters predicted TAI success or PPV requirement (all p > 0.05). Dexamethasone implants, with their larger applicator, carried the highest risk. Among anti-VEGFs, PFS ranibizumab demonstrated the most favourable safety profile, with the lowest incidence of PIE. Manual immediate-use bevacizumab aliquoting is a safe, cost-effective alternative in resource-limited settings. In univariate analysis, culture positivity emerged as a negative prognostic factor, though this finding is limited by small sample sizes. Given unpredictable TAI responses, aggressive monitoring and a low PPV threshold are essential.
Park Noa N, Abdolrahimi Shiva S, Behrens Sue S
Antimicrobial preservatives (APs) offer significant advantages when included in multi-dose vaccines (MDVs) and biologics. In addition to reducing medical waste and optimizing overall manufacturing efficiency, MDVs with APs increase global access to critical medicines and meet public health demands. Phenol, metacresol, benzyl alcohol, benzethonium chloride, thimerosal, and phenoxyethanol are currently the only APs included in FDA-approved biologics and WHO prequalified vaccines. The mechanisms of actions of these six APs, however, may limit their suitability for certain biologics, namely RNA-based vaccines. Novel antimicrobial agents, such as zinc salts and chitosan, may be considered for further investigation and potential use as alternative APs. Including APs in biologics gives rise to additional manufacturing considerations pertaining to drug product quality and stability. In addition, antimicrobial agents have not yet been tested or approved for use in RNA-based vaccines, which highlights important implications for access and shelf-life.
Mela Liverinto-Panagiotis LP
Zhong Jieying J
Biologics have shifted therapeutic ambition in severe asthma from disease control toward clinical remission. However, on-treatment remission remains a treatment state rather than proof of disease modification because residual biological, physiological, or structural abnormalities may persist and benefits observed during ongoing exposure cannot distinguish pharmacological suppression from durable change in disease course. This review evaluates disease-modifying potential within a multidomain interpretive framework spanning clinical remission, biological change, physiological recovery, structural change, longitudinal trajectory, and durability as pharmacological exposure is reduced or withdrawn. Human mechanistic and clinical studies show that biologics can alter selected local-airway biological processes and, in some settings, physiological abnormalities, although responses across domains may dissociate. Structural effects are endpoint-dependent: mucus-plug burden is treatment responsive, and selected airway-wall remodeling features may change in defined cohorts, but universal or synchronous structural reversal has not been established. Earlier biologic initiation is associated with better subsequent outcomes, yet causal modification of long-term trajectory remains unproven. Withdrawal and dose-spacing studies show heterogeneous durability and variable pharmacological dependence, with both disease re-emergence and persistent benefit. Biologics can achieve profound disease suppression and selected disease-domain changes relevant to a disease-modifying interpretation. However, current evidence does not establish universal, durable disease modification or cure. Confidence in a disease-modifying interpretation would increase with convergent evidence of underlying-process change, altered longitudinal trajectory, and durability beyond continuous pharmacological exposure.
Awadhi Sameer Al SA, Khassouan Ahmed Mohammed AM, Georgopoulos Filippos F, Alfalasi Moza M et al.
This study evaluates the disease burden, treatment patterns, and healthcare resource utilization among patients with ulcerative colitis (UC) from Dubai, United Arab Emirates. The study was conducted from January 1, 2014, to September 30, 2023, using the Dubai Real-world e-claims database. The initial observed diagnosis of UC, whether principal, secondary, or occurring upon hospital admission, was termed the index diagnosis date. The timeframe spanning from January 1, 2014, to September 30, 2022, was referred to as the index period. Patients with a first observed diagnosis claim for UC any time during the index period were analyzed overall and by treatment cohort. Cohort 1 comprised patients treated with conventional therapies like corticosteroids, immunomodulators, and 5-aminosalicylic acid (5-ASA). Cohort 2 included patients whose ongoing treatment regimen involved advanced options, such as biologics and targeted synthetic small molecules. The study included 11,812 patients (median age: 38 years). Among 5618 patients with available sex data, 61.9% were male and 38.1% were female. The annual claims-based proportion of prevalent patients with UC ranged from 0.07% to 0.10% from 2014 to 2022, with no consistent year-over-year increase. Reported comorbidities included immune-mediated disorders (25.6%), psychological disorders (4.8%), and other comorbidities (34.8%). 5-ASA (91.6%) and corticosteroids (33.6%) were commonly prescribed, followed by biologics (6.9%). In the overall cohort, the median all-cause and disease-specific costs incurred were USD 2703.40 and USD 1314.70, respectively. The median disease-specific costs incurred for immune-mediated disorders, psychological disorders, and other comorbidities were USD 407.10, USD 333.10, and USD 461.40, respectively, during the 12-month post-index period. The study cohort reported a high disease burden, frequent comorbidities, and significant healthcare costs. Most patients were treated primarily with conventional therapies such as 5-ASA and corticosteroids, while newer treatments such as biologics were used as advanced therapies. Additional research is needed to assess whether biologics and newer treatments reduce the disease burden of UC in Dubai.
注册免费账户还可查看另外 9996 篇文献
免费注册查看全部文献 →